Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
BMC Anesthesiol ; 23(1): 140, 2023 04 27.
Artigo em Inglês | MEDLINE | ID: mdl-37106321

RESUMO

BACKGROUND: The optimal time to intubate patients with SARS-CoV-2 pneumonia has not been adequately determined. While the use of non-invasive respiratory support before invasive mechanical ventilation might cause patient-self-induced lung injury and worsen the prognosis, non-invasive ventilation (NIV) is frequently used to avoid intubation of patients with acute respiratory failure (ARF). We hypothesized that delayed intubation is associated with a high risk of mortality in COVID-19 patients. METHODS: This is a secondary analysis of prospectively collected data from adult patients with ARF due to COVID-19 admitted to 73 intensive care units (ICUs) between February 2020 and March 2021. Intubation was classified according to the timing of intubation. To assess the relationship between early versus late intubation and mortality, we excluded patients with ICU length of stay (LOS) < 7 days to avoid the immortal time bias and we did a propensity score and a cox regression analysis. RESULTS: We included 4,198 patients [median age, 63 (54‒71) years; 71% male; median SOFA (Sequential Organ Failure Assessment) score, 4 (3‒7); median APACHE (Acute Physiology and Chronic Health Evaluation) score, 13 (10‒18)], and median PaO2/FiO2 (arterial oxygen pressure/ inspired oxygen fraction), 131 (100‒190)]; intubation was considered very early in 2024 (48%) patients, early in 928 (22%), and late in 441 (10%). ICU mortality was 30% and median ICU stay was 14 (7‒28) days. Mortality was higher in the "late group" than in the "early group" (37 vs. 32%, p < 0.05). The implementation of an early intubation approach was found to be an independent protective risk factor for mortality (HR 0.6; 95%CI 0.5‒0.7). CONCLUSIONS: Early intubation within the first 24 h of ICU admission in patients with COVID-19 pneumonia was found to be an independent protective risk factor of mortality. TRIAL REGISTRATION: The study was registered at Clinical-Trials.gov (NCT04948242) (01/07/2021).


Assuntos
COVID-19 , Pneumonia , Síndrome do Desconforto Respiratório , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , COVID-19/terapia , Estado Terminal/terapia , Mortalidade Hospitalar , Unidades de Terapia Intensiva , Intubação Intratraqueal , Oxigênio , Respiração Artificial , Estudos Retrospectivos , SARS-CoV-2
2.
Med Intensiva ; 33(1): 40-9, 2009.
Artigo em Espanhol | MEDLINE | ID: mdl-19232208

RESUMO

Spain has a rate of 34.4 donors per million population, making it the country with the highest rate of organ donation all over the world. In spite of these values, need of lungs for transplantation is always greater than the number of organs obtained. The adrenergic storming produced during brain herniation and the initiation of a brain death condition entail a series of pathophysiological alterations that can endanger the lung viability. In this paper, we review the evaluation of lung donor and its maintenance. In all the potential lung donors, the Apnea Test with CPAP should be done and the criteria for the donation of the lung under ideal conditions and with expanded criteria lung donors are reviewed. The protocol of aggressive maintenance including a protective ventilation strategy, restricted fluid intake, use of prophylactic antibiotics, corticosteroids and the systematic use of measures aimed at avoiding alveolar collapse together with maneuvers aimed at achieving better lung recruitment can improve the management of the lung donor and obtain a greater number of organs for transplantation.


Assuntos
Transplante de Pulmão , Pulmão/fisiopatologia , Doadores de Tecidos , Coleta de Tecidos e Órgãos/métodos , Adolescente , Adulto , Idoso , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Apneia , Morte Encefálica/diagnóstico , Morte Encefálica/fisiopatologia , Pressão Positiva Contínua nas Vias Aéreas , Contraindicações , Humanos , Transplante de Pulmão/estatística & dados numéricos , Metilprednisolona/administração & dosagem , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Preservação de Órgãos/métodos , Seleção de Pacientes , Respiração Artificial , Doadores de Tecidos/estatística & dados numéricos , Sobrevivência de Tecidos/efeitos dos fármacos , Sobrevivência de Tecidos/fisiologia , Coleta de Tecidos e Órgãos/normas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA